Latest News for: tdp-43

Edit

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Rutland Herald 14 Jan 2026
VICTORIA, British Columbia--(BUSINESS WIRE)--Jan 14, 2026-- ....
Edit

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease (Form 6-K) (MindWalk Holdings Corp)

Public Technologies 14 Jan 2026
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease ... Intrabodies Selective for Pathogenic TDP-43, is available on bioRxiv (DOI.
Edit

Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases

Nasdaq Globe Newswire 08 Jan 2026
First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury ... .
Edit

Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment

Hastings Tribune 08 Jan 2026
... across TDP-43 proteinopathies including Traumatic Brain Injury and .
Edit

Prothena Announces Poster Presentation on its TDP-43 CYTOPE� Program at Neuroscience 2025

Business Wire 20 Nov 2025
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE� Program at Neuroscience 2025 ... .
Edit

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

The Galveston Daily News 19 Nov 2025
DUBLIN, Ireland--(BUSINESS WIRE)--Nov 19, 2025-- ....
  • 1

Article Search

tools
×
×
×
×